{
    "organizations": [],
    "uuid": "6561cd826c3c1957e86d9034ae7fd158a7ee0700",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ra-pharmaceuticals-announces-prese/brief-ra-pharmaceuticals-announces-presentation-of-ra101495-sc-phase-2-gmg-clinical-trial-design-at-70th-annual-aan-meeting-idUSASC09X98",
    "ord_in_thread": 0,
    "title": "BRIEF-Ra Pharmaceuticals Announces Presentation Of RA101495 SC Phase 2 gMG Clinical Trial Design At 70Th Annual AAN Meeting",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Ra Pharmaceuticals Inc:\n* RA PHARMACEUTICALS ANNOUNCES PRESENTATION OF RA101495 SC PHASE 2 GMG CLINICAL TRIAL DESIGN AT THE 70TH ANNUAL AAN MEETING\n* RA PHARMACEUTICALS INC - REMAINS ON TRACK TO REPORT DATA FROM RA101495 SC PHASE 2 GMG STUDY IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T14:17:00.000+03:00",
    "crawled": "2018-04-25T14:30:22.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "ra",
        "pharmaceutical",
        "inc",
        "ra",
        "pharmaceutical",
        "announces",
        "presentation",
        "ra101495",
        "sc",
        "phase",
        "gmg",
        "clinical",
        "trial",
        "design",
        "70th",
        "annual",
        "aan",
        "meeting",
        "ra",
        "pharmaceutical",
        "inc",
        "remains",
        "track",
        "report",
        "data",
        "ra101495",
        "sc",
        "phase",
        "gmg",
        "study",
        "first",
        "half",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}